Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HyQvia · 1 trial · 1 indication
Measurement of isometric muscle strength of four involved muscle groups
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia |
| Group B | EXPERIMENTAL | 24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) |
| Name | Type | Description |
|---|---|---|
| HyQvia | DRUG | Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection |
| Subcuvia | DRUG | Human immunoglobulin 16% for subcutaneous injection |
Inclusion Criteria: * Age at onset 18 - 65 years. * The presence of asymmetrical limb weakness at onset or motor involvement having a motor nerve distribution in at least two peripheral nerve distributions, predominant upper limb involvement, disabling weakness MRC grade 4 or less in at least one m...
HyQvia is an investigational therapy being studied for the treatment of Multifocal Motor Neuropathy (MMN), a neurological condition. It is a small molecule developed by Baxter International Inc. (NYSE: BAX). HyQvia is currently in Phase 2 clinical development for this indication.
HyQvia is a small molecule, but its specific molecular target has not been disclosed. It is being studied for its efficacy and safety in patients with Multifocal Motor Neuropathy (MMN), a condition affecting motor nerves.
HyQvia is developed by Baxter International Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BAX. The company is conducting clinical research to evaluate HyQvia as a potential treatment for Multifocal Motor Neuropathy.
HyQvia is in Phase 2 clinical development for Multifocal Motor Neuropathy. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
HyQvia has been studied in one completed Phase 2 clinical trial, identified as NCT02556437. This trial, titled 'Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)', enrolled 18 participants in Denmark and was a controlled, randomized study.
HyQvia is also known as Immunoglobulin 10% with Recombinant Hyaluronidase, as referenced in clinical trial NCT02556437. This name describes its composition, which includes immunoglobulin and recombinant hyaluronidase, and it is being investigated for Multifocal Motor Neuropathy.